Haynes R, McDonald H, Garg A, Montague P. Interventions for helping patients follow prescription medications. Cochrane Database of Systematic Reviews. 2003;1.
Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23):1903–07.
Lindholm L, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545–53.
Rudd P. Review: beta-blockers are less effective than other antihypertensive drugs for reducing stroke in primary hypertension. ACP Journal Club. 2006;144(3):67.
Bradley H, Wiysinge C, Volmink J, Mayosi B, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24:2131–41.
Khan N, McAlister F. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737–42.
Ko D, Hebert P, Coffey C, Sedrakyan A, Curtis J, Krumholz H. Beta-blocker therapy and symptoms of depression, fatigue and sexual dysfunction. JAMA. 2002;288(3):351–57.
Ko D, Hebert P, Coffey C, Curtis J, Foody J, Sedrakyan A, et al. Adverse effects of beta-blocker therapy for patients with heart failure. Arch Intern Med. 2004;164:1389–94.
Carlberg B, Samuelsson O, Lindholm L. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684–89.
Soriano J, Hoes A, Meems L, Grobbee D. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardioavsc Dis. 1997;39(5):445–56.
ALLHAT Officers. Major outcomes in the high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. JAMA 2002;288:2981–97.
Dahlof B, Sever P, Poulter N, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895–906.
Poulter N, Wedel H, Dahlof B, Sever P, Beevers DG, Caulfield M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366(9489):901–13.
